In the latest trading session, Aphria Inc. closed at $9.17, marking a -0.33% move from the previous day. This change lagged the S&P 500's 0.36% gain on the day. Elsewhere, the Dow gained 0.36%, while the tech-heavy Nasdaq added 0.34%.
Heading into today, shares of the company had lost 9.72% over the past month, lagging the Medical sector's loss of 0.3% and the S&P 500's gain of 0.64% in that time.
Investors will be hoping for strength from APHA as it approaches its next earnings release. The company is expected to report EPS of -$0.04, down 166.67% from the prior-year quarter. Meanwhile, the Zacks Consensus Estimate for revenue is projecting net sales of $41.11 million, up 403.74% from the year-ago period.
APHA's full-year Zacks Consensus Estimates are calling for earnings of $0.11 per share and revenue of $129.24 million. These results would represent year-over-year changes of -21.43% and +344.96%, respectively.
Any recent changes to analyst estimates for APHA should also be noted by investors. Recent revisions tend to reflect the latest near-term business trends. With this in mind, we can consider positive estimate revisions a sign of optimism about the company's business outlook.
Our research shows that these estimate changes are directly correlated with near-term stock prices. We developed the Zacks Rank to capitalize on this phenomenon. Our system takes these estimate changes into account and delivers a clear, actionable rating model.
The Zacks Rank system, which ranges from #1 (Strong Buy) to #5 (Strong Sell), has an impressive outside-audited track record of outperformance, with #1 stocks generating an average annual return of +25% since 1988. Within the past 30 days, our consensus EPS projection remained stagnant. APHA currently has a Zacks Rank of #3 (Hold).
Digging into valuation, APHA currently has a Forward P/E ratio of 81.78. For comparison, its industry has an average Forward P/E of 25.33, which means APHA is trading at a premium to the group.
The Medical - Products industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 91, which puts it in the top 36% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
To follow APHA in the coming trading sessions, be sure to utilize Zacks.com.
Image: Bigstock
Aphria Inc. (APHA) Stock Sinks As Market Gains: What You Should Know
In the latest trading session, Aphria Inc. closed at $9.17, marking a -0.33% move from the previous day. This change lagged the S&P 500's 0.36% gain on the day. Elsewhere, the Dow gained 0.36%, while the tech-heavy Nasdaq added 0.34%.
Heading into today, shares of the company had lost 9.72% over the past month, lagging the Medical sector's loss of 0.3% and the S&P 500's gain of 0.64% in that time.
Investors will be hoping for strength from APHA as it approaches its next earnings release. The company is expected to report EPS of -$0.04, down 166.67% from the prior-year quarter. Meanwhile, the Zacks Consensus Estimate for revenue is projecting net sales of $41.11 million, up 403.74% from the year-ago period.
APHA's full-year Zacks Consensus Estimates are calling for earnings of $0.11 per share and revenue of $129.24 million. These results would represent year-over-year changes of -21.43% and +344.96%, respectively.
Any recent changes to analyst estimates for APHA should also be noted by investors. Recent revisions tend to reflect the latest near-term business trends. With this in mind, we can consider positive estimate revisions a sign of optimism about the company's business outlook.
Our research shows that these estimate changes are directly correlated with near-term stock prices. We developed the Zacks Rank to capitalize on this phenomenon. Our system takes these estimate changes into account and delivers a clear, actionable rating model.
The Zacks Rank system, which ranges from #1 (Strong Buy) to #5 (Strong Sell), has an impressive outside-audited track record of outperformance, with #1 stocks generating an average annual return of +25% since 1988. Within the past 30 days, our consensus EPS projection remained stagnant. APHA currently has a Zacks Rank of #3 (Hold).
Digging into valuation, APHA currently has a Forward P/E ratio of 81.78. For comparison, its industry has an average Forward P/E of 25.33, which means APHA is trading at a premium to the group.
The Medical - Products industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 91, which puts it in the top 36% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
To follow APHA in the coming trading sessions, be sure to utilize Zacks.com.